# Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

> **NCT06813365** · PHASE1 · RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 190 (estimated)

## Conditions studied

- Nonsmall-cell Lung Cancer

## Interventions

- **DRUG:** DZD6008

## Key facts

- **NCT ID:** NCT06813365
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06813365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06813365, "Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06813365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*